Abstract: The present disclosure provides a method for predicting a lattice defect in a metal-organic framework (MOF) membrane. The method comprises acquiring a number n of a ligand during preparation of the MOF membrane, and acquiring a theoretical number m of connections formed between a core secondary building unit and a surrounding secondary building unit; setting a number of collisions of the ligand with the core secondary building unit and the surrounding secondary building unit; and calculating an expected value of a number of connections formed on lattices based on a collision probability, wherein the number of collisions is 1 or 2.

Abstract: The present disclosure relates to a mixed matrix carbon molecular sieve (CMS) membrane, a preparation method of the mixed matrix CMS membrane, and use of the mixed matrix CMS membrane in C2H4/C2H6 separation, and belongs to the technical field of membrane separation. The present disclosure solves the problem that the CMS materials in the prior art exhibit low selectivity and low flux during an ethylene/ethane separation process. In this patent, C3N4 is used as a filling particle to prepare a mixed matrix membrane (MMM), and the MMM is pyrolyzed to prepare a CMS membrane. The C3N4/6FDA-DAM MMM has prominent C2 separation performance.

Abstract: The present disclosure relates to a mixed matrix carbon molecular sieve (CMS) membrane, a preparation method of the mixed matrix CMS membrane, and use of the mixed matrix CMS membrane in C2H4/C2H6 separation, and belongs to the technical field of membrane separation. The present disclosure solves the problem that the CMS materials in the prior art exhibit low selectivity and low flux during an ethylene/ethane separation process. In this patent, C3N4 is used as a filling particle to prepare a mixed matrix membrane (MMM), and the MMM is pyrolyzed to prepare a CMS membrane. The C3N4/6FDA-DAM MMM has prominent C2 separation performance.

Abstract: A use of an enhancer of rudimentary homolog (ERH) or a fragment thereof, in the preparation of a reagent for monitoring drug efficacy for rheumatoid arthritis, is provided. 35 proteins as candidate ACPA-negative RA autoantigens, 8 proteins as candidate autoantigens for predicting disease activity, and 6 proteins as candidate autoantigens for predicting treatment effect were screened by hybridizing high density protein chips with RA serum. Of the 6 proteins as candidate autoantigens for predicting treatment effect, one autoantigen, ERH, can successfully determine the effect of drug treatment on RA, and the AUC for predicting efficacy may be up to 0.733.

Abstract: The invention provides a use of a deoxyhypusine dioxygenase DOHH or a fragment thereof in the preparation of a reagent for diagnosing an anti-citrulline polypeptide antibody-negative rheumatoid arthritis disease. 35 proteins as candidate ACPA-negative RA autoantigens were screened by hybridizing high density protein chips with RA serum. 4 protein antigens (DOHH, DUSP11, PTX3 and PAGE5) were identified as having high sensitivity and specificity in the ACPA-negative serum of RA, wherein DOHH can be used as the ACPA-negative RA diagnostic markers.

Abstract: A use of a pentaxin-related protein 3 (PTX3) or a fragment thereof, in the preparation of a reagent for diagnosing an anti-citrulline polypeptide antibody-negative rheumatoid arthritis disease, is provided. 35 proteins as candidate ACPA-negative RA autoantigens were screened by hybridizing high density protein chips with RA serum. 4 protein antigens were identified as having high sensitivity and specificity in the ACPA-negative serum of RA, and all were newly discovered autoantigens (DOHH, DUSP11, PTX3, and PAGE5). The invention indicates that DOHH, DUSP11, PTX3, and PAGE5 can be used as ACPA-negative RA diagnostic markers.

Abstract: A biological capture device including an elongate member configured to be inserted into a region of a body of a subject and having capture region on the surface of the elongate member containing a capture ligand capable of binding to a target biological material when the device is in the body, and methods of use of the device to detect and measure target biological materials in a body.

Abstract: The present invention relates to a mineral processing technology and method for refractory chalcopyrite ores, particularly to a mineral processing technology and method for the separation of chalcopyrite from multiple natural types of copper ores containing chalcopyrite, pyrrhotite, talc and serpentine, which belongs to the technical field of mineral processing. It's characterized by: conducting a two-stage grinding on the chalcopyrite ore, with each grinding stage followed by size grading, and treating ores in different size fractions separately, wherein coarse-grain ores are separated in the presence of xanthate, with calcium oxide and CMC controlling the pH and acting as depressor respectively, while fine-grained ores are subjected to rougher in the presence of kerosene, and subsequently subjected to cleaner in the presence of xanthate.

Abstract: The present invention relates to a mineral processing technology and method for refractory chalcopyrite ores, particularly to a mineral processing technology and method for the separation of chalcopyrite from multiple natural types of copper ores containing chalcopyrite, pyrrhotite, talc and serpentine, which belongs to the technical field of mineral processing. It's characterized by: conducting a two-stage grinding on the chalcopyrite ore, with each grinding stage followed by size grading, and treating ores in different size fractions separately, wherein coarse-grain ores are separated in the presence of xanthate, with calcium oxide and CMC controlling the pH and acting as depressor respectively, while fine-grained ores are subjected to rougher in the presence of kerosene, and subsequently subjected to cleaner in the presence of xanthate.

Abstract: The present application relates to Multicomponent Nucleic Acid Enzymes (MNAzymes), which may be used for detecting, identifying and/or quantifying targets. More particularly, this application provides methods of designing and making more reliable MNAzymes, as well as compositions comprising MNAzyme components and methods of using MNAzymes.

Abstract: An electrochemical sensor comprising an electrode having a protective layer; conductive nanoparticles bound to the protective layer; a redox active species bound to the conductive nanoparticles; and a binding moiety capable of associating with an analyte, the binding moiety being associated with the redox active species bound to the conductive nanoparticles. Association of a binding moiety with the analyte modulates the electrochemistry of the redox active species.

Abstract: A method for detecting the presence of an analyte in a sample. The method comprises the steps of: adding to the sample an antibody of the analyte; exposing to the sample a binding moiety capable of becoming associated with the antibody of the analyte, the binding moiety being associated with a redox active species that is bound to an electrode and electrochemically accessible to the electrode; and taking amperometric electrochemical measurements which indicate whether the electrochemistry of the redox active species has been modulated by the binding moiety associating with the antibody of the analyte.

Abstract: The present application relates to Multicomponent Nucleic Acid Enzymes (MNAzymes), which may be used for detecting, identifying and/or quantifying targets. More particularly, this application provides methods of designing and making more reliable MNAzymes, as well as compositions comprising MNAzyme components and methods of using MNAzymes.

Abstract: Disclosed herein is an electrochemical sensor for detecting an analyte. The sensor comprises an electrode, a redox active species that is electrochemically accessible to the electrode, and a binding moiety capable of associating with the analyte, wherein association of the binding moiety with the analyte affects the electrochemistry of the redox active species. Also disclosed herein is a method for detecting the presence of an analyte in a sample.

Abstract: The invention relates to methods and kits for detecting thyroid cancer by detecting differences in the expression of genes that are differentially expressed in thyroid cancer cells.

Abstract: Disclosed herein is an electrochemical sensor for detecting an analyte. The sensor comprises an electrode, a redox active species that is electrochemically accessible to the electrode, and a binding moiety capable of associating with the analyte, wherein association of the binding moiety with the analyte affects the electrochemistry of the redox active species. Also disclosed herein is a method for detecting the presence of an analyte in a sample.